Page 175

175. The Optic Neuritis Study Group. 1997. Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol.; 115: 1545-52.

176. Thompson AJ, Polman C, Hohlfeld R, eds. 1997. Multiple Sclerosis: Clinical Challenges and Controversies. London. Martin Dunitz.

177. Tilbery CP, Atra M, Oliveira AS, Calia LA, Schmidt B. 1989. [Histochemical study of the skeletal muscle in multiple sclerosis]. Arq Neuropsiquiatr.; 47: 337-45.

178. Trask PC, Esper P, Riba M, Redman B. 2000. Psychiatric side effects of interferon therapy: Prevalence, proposed mechanisms, and future directions. J. Clin Oncology.; 18: 2316-2326.

179. Valiquette G, Herbert J, Maede-D'Alisera P. 1996. Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial. Arch Neurol.; 53: 1270-5.

180. Van den Burg W, van Zomeren AH, Minderhoud JM, Prange AJ, Meijer NS. 1987. Cognitive impairment in patients with multiple sclerosis and mild physical disability. Arch Neurol.; 44: 494-501.

181. Vas CJ. 1969. Sexual impotence and some autonomic disturbances in men with multiple sclerosis. Acta Neurol Scand.; 45: 166-82.

182. Vercoulen JH, Hommes OR, Swanink CM, et al. 1996. The measurement of fatigue in patients with multiple sclerosis. A multidimensional comparison with patients with chronic fatigue syndrome and healthy subjects. Arch Neurol.; 53(7): 642-649.

183. Vermote R, Ketelaer P, Carton H. 1986. Pain in multiple sclerosis patients. A prospective study using the Mc Gill Pain Questionnaire. Clin Neurol Neurosurg.; 88: 87-93.

184. Vidal J, Curcoll L, Roig T, Bagunya J. 1995. Intracavernous pharmacotherapy for management of erectile dysfunction in multiple sclerosis patients. Rev Neurol.; 23: 269-71.

185. Walther EU, Hohlfeld R. 1999. Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology.; 53: 1622-7.

186. Waxman SG, Kocsis JD, Black JA. 1994. Type III sodium channel mRNA is expressed in embryonic but not adult spinal sensory neurons, and is reexpressed following axotomy. J Neurophysiol.; 72: 466-70.

187. Weiller C, May A, Limmroth V, et al. 1995. Brain stem activation in spontaneous human migraine attacks. Nat Med.; 1: 658-60.

188. Weinshenker BG, Penman M, Bass B, Ebers GC, Rice GP. 1992. A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology.; 42: 1468-71.

189. Wells KBSA, Hays RD, Burnam MA, et al. 1989. The functioning and well-being of depressed patients. Results from the medical outcomes study. JAMA.; 262: 914-919.

190. Werring DJ, Bullmore ET, Toosy AT, et al. 2000. Recovery from optic neuritis is associated with a change in the distribution of cerebral response to visual stimulation: a functional magnetic resonance imaging study. J Neurol Neurosurg Psychiatry.; 68: 441-9.

191. Whittle IR, Hooper J, Pentland B. 1998. Thalamic deep-brain stimulation for movement disorders due to multiple sclerosis. Lancet.; 351: 109-10.

192. Wikstrom J, Poser S, Ritter G. 1980. Optic neuritis as an initial symptom in multiple sclerosis. Acta Neurol Scand.; 61: 178-85.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement